Our Executive Team

Our highly experienced executive team is dedicated to drug research and development. Reven strives to provide the highest quality medicines to safely treat diseases rooted in inflammation and immune malfunction to the global market. 

Peter Lange

Co-Founder, CEO
Mr. Lange was one of the Co-founders of Reven and helped build the management team that currently drives the company.

Brian Denomme

Co-Founder, President
Mr. Denomme is a Co-Founder of Reven Pharmaceuticals with 30 years of International Executive Management experience.

Michael Volk

Co-Founder, Chief Strategy Officer
Mr. Volk has 24 years of International Executive Management experience, 20 of which have been in Healthcare, Pharmaceuticals, and Biotech.

Fatih M. Uckun, M.D., Ph.D

Executive Vice President, Global Head of Clinical and Medical Affairs
Dr. Uckun is a physician-scientist with more than 30 years of professional experience in developmental therapeutics and biopharmaceuticals in oncology/immune-oncology as well as infectious diseases and immunology

Henk Van Wyk

Chief Scientist
Mr. Van Wyk brings over 40 years of experience in the pharmaceutical industry, including research, development, drug design and formulation.

Jeffrey B. Halverson

Chief Financial Officer
Mr. Halverson is known as an exceptional leader with effective management and team building skills. As an experienced banking executive, he has an impressive 30-plus year track record of opening and growing banking organizations.

Daniel Hoffman

Chief Operating Officer
Mr. Hoffman has more than 20 years of Executive Management & Corporate Leadership experience, with a proven track record of success.

James Carlson, Pharm.D.

Executive VP of Development
Dr. Carlson has over 40 years in the pharmaceutical industry with expertise in product development. He co-founded and later owned PRACS Institute, Ltd., a contract research organization contracted by the drug industry for unbiased product evaluation for FDA submission.

Kevin McGovern

Kevin McGovern is the Chairman and CEO of McGovern Capital. Through McGovern Capital and its affiliates, he has co-founded over twenty-five (25) companies, six of which have become world/category leaders.

Our Advisory Board

Dr. Jürgen Lüders is currently employed at Saint Mary’s Mercy Health Neurosurgeon with a specialty in complex spine, epilepsy surgery and brain tumors.

 📄 View Resume

Dr. Grossman is a Professor of Internal Medicine in the Division of Cardiovascular Medicine at the University of Michigan and a staff cardiologist at the VA Ann Arbor. He is the Director of the Cardiac Catheterization Laboratory at the VA Ann Arbor, Director of the Blue Cross Blue Shield of Michigan Cardiovascular Consortium Peripheral Vascular Intervention (BMC2 PVI), and Co-director of the University of Michigan Cardiovascular Center Multidisciplinary Peripheral Arterial Disease Program. He completed his MD at the University of Nebraska, his residency at the University of California San Diego, where he also served as chief resident, and his cardiology and interventional cardiology fellowships at the University of Michigan. Dr. Grossman is an interventional cardiologist with clinical interest in catheter based treatment of coronary, peripheral arterial, structural heart and valvular heart disease. His academic interests are focused on quality improvement in management of peripheral arterial disease and therapeutic angiogenesis.

📄 View Resume

Dr. Kowalski is board certified by the American Board of Neurological Surgery and is a Fellow of both the American Association of Neurological Surgeons and the American College of Surgeons. His practice encompasses all aspects of cranial and spinal surgery with particular emphasis on motion preservation technologies, minimally invasive surgery (MIS) techniques, and spinal instrumentation.

📄 View Resume

Specializing in Melanoma Oncology, Dr. Woodman has a board certification from The American Board of Internal Medicine.

📄 View Resume